Українська English

ISSN 2522-9028 (Print)
ISSN 2522-9036 (Online)
DOI: https://doi.org/10.15407/fz

Fiziologichnyi Zhurnal

is a scientific journal issued by the

Bogomoletz Institute of Physiology
National Academy of Sciences of Ukraine

Editor-in-chief: V.F. Sagach

The journal was founded in 1955 as
1955 – 1977 "Fiziolohichnyi zhurnal" (ISSN 0015 – 3311)
1978 – 1993 "Fiziologicheskii zhurnal" (ISSN 0201 – 8489)
1994 – 2016 "Fiziolohichnyi zhurnal" (ISSN 0201 – 8489)
2017 – "Fiziolohichnyi zhurnal" (ISSN 2522-9028)

Fiziol. Zh. 2016; 62(2): 87-93

KORVITIN REDUCES THE HIGH MAINTENANCE OF MYELOPEROXIDASE IN PLASMA OF BLOOD OF PATIENTS WITH THE ACUTE INFARCT OF MYOCARDIUM

N.O. Ryzhkova, T.I. Gavrilenko, O.M. Parkhomenko

    “NSC “M.D. Strazhesko Institute of Cardiology NAMS of Ukraine”, Kyiv, Ukraine
DOI: https://doi.org/10.15407/fz62.02.087


Abstract

We studied the content of myeloperoxidase in plasma of blood, which is a new additional marker of the metabolic activity of phagocytes and the activity of inflammation in patientes with the acute infarct of myocardium and possibility of its correction of Korvitin. We inspected 15 practically healthy persons in which the content of myeloperoxidase was 74,5±16,3 ng/ml, 13 patients with a stable stenocardia (the conent of myeloperoxidase was 218,4±30,9 ng/ml) and 60 patients with acute infarct of myocardium (the content of myeloperoxidase was 606,0±59,3 ng/ml at the beginning of therapy) in the dynamics of treatment. In patients accepting standard treatment (without application of Korvitin), the content of myeloperoxidase was unchanged during 7 days of treatment. It patients administered korvitin, the action of this preparation depended on the initial level of myeloperoxidase. In Patients with the initial normal plasma content of myeloperoxidase (16,7%), its content insignificantly increased during the time course of the treatment, while in patients with the high initial level of myeloperoxidase (83,3%), its level declined during treatment.

Keywords: acute infarct of myocardium; myeloperoxidase; korvitin.

Full text: (PDF, in Ukrainian)

References

  1. Gavrilenko T, Ryzhkova N, Parkhomenko O. Myeloperoxidaseand its role in development of ischemic heartdeseases. Ukr Card J 2014; 4: 119-26. [Russian].
    2.  
  2. Salonen I, Huttunen K, Hirvonen M, Dufva J, GroundstroemK, Dufva H, Pekkanen J, Salonen R. Serummyeloperoxidase is independent of the risk factors ofatherosclerosis. Coron Artery Dis. 2012; 23(4): 251-8. CrossRef PubMed
    3.  
  3. Agner K. Verdoperoxidase. A ferment isolated from leucocytes.Acta Chem Scand. 1941; A2 (S.8): 1-62.
    4.  
  4. Klebanoff S. Myeloperoxidase: Friend and foe. J LeucBiol. 2005; 77(5): 598-625. CrossRef  
  5. Peluso I, Morabito G, Urban L, Ioannone F, Serafini M.Oxidative stress in atherosclerosis development: thecentral role of LDL and oxidative burst. Endocr MetabImmune Disord Drug Targets. 2012; 12(4): 351-60. CrossRef  
  6. Ruleva N, Zvyaginceva M, Dugin S. Myeloperoxidase:biological functions and clinical value. Modern SciTechnol. 2007; 8: 11-14. [Russian].
    7.  
  7. Alipour A, Ribalta J, Njo T, Janssen H, Birnie E, vanMiltenburg A, Elte J, Castro C. Trans-vessel gradient ofmyeloperoxidase in coronary artery disease. Eur J ClinInvest . 2013; 43(9): 920-5. CrossRef PubMed
    8.  
  8. Patterson E, Fraser D, Capretta A, Potter R, Cepinskas G.Carbon monoxide-releasing molecule 3 inhibits myeloperoxidaseand protects against MPO-induced vascularendothelial cell activation/dysfunction. Free Radic BiolMed. 2014; 26 (70C): 167-73.
    9.  
  9. Kolarova H, Klinke A, Kremserova S, Adam M, PekarovaM, Baldus S, Eiserich J, Kubala L. Myeloperoxidaseinduces the priming of platelets. Free Radic Biol Med.2013; Aug;61:357-69.
    10.  
  10. Graner M, Tikkanen E, Rimpila O, Tikkanen H, Ripatti S,Lokki M, Niemen M, Taskinen M, Sinisalo J. Diagnosticefficacy of myeloperoxidase to identify acute coronarysyndrome in subjects with chest pain. Ann Med. 2013;Jun;45(4): 322-7.
    11.  
  11. Moybenko O, Dosenko V, Parkhomenko O. Endogenousmechanisms of cardioprotection as basis of nosotropictherapy of diseases of heart. Kyiv: Scientific thinking;2008. [Russian ] .
    12.  
  12. Kozhukhov S, Parkhomenko А. Myocardial protection byintravenous 5-lipoxygenase inhibitor Quercetin administrationbefore primary angioplasty in patients with acutemyocardial infarction: short-term results an open blindrandomized trial. J Am Coll Cardiol .2007; 49(9): 226A.
    13.  
  13. Van de Werf F, Bax J, Betriu A, Blomstrom-Lundquist C,Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati A,Rosengren A, Steg P, Tubaro M, Verheugt F, Weidinger F,Weis M. Management of acute myocardial infarction inpatients presenting with persistent ST-segment elevation:the Task Force on the Management of ST-Segment ElevationAcute Myocardial Infarction of the European Societyof Cardiology. Eur. Heart J .2008; 29(23): 2909-45.
    14.  
  14. Dullaart RP, Tietge UJ, Kwakernaak A, Dikkeschei BD,Perton F, Tio RA. Alterations in plasma lecithin: cholesterol acyltransferase and myeloperoxidase in acute myocardialinfarction. Atherosclerosis. 2014; 234(1):185-92. CrossRef PubMed
    15.  
  15. Oemrawsingh R, Lenderink T, Akkerhuis K, HeeschenC, Baldus S, Fichtlscherer S, Hamm C, Simoons M, BoersmaE. Multimarker risk model conteining troponin-T,interleukin 10, myeloperoxidase and placental growthfactor predicts long-term cardiovascular risk after nonST-segmentelevation acute coronary syndrome. Heart.2011; 97(13): 1061-6. CrossRef PubMed
    16.  
  16. Kajer T, Fairfull-Smith K, Yamasaki T, Yamada K,Fu S, Bottle S, Hawkins C, Davies M. Inhibition ofmyeloperoxidase- and neutrophil-mediated oxidantproduction by tetraethyl and tetramethyl nitroxides. FreeRadic Biol Med .2014; May;70: 96-105 .
    17.  
  17. Ryzhkova N, Gavrilenko T, Parkhomenko O, KozhukhovS. Metabolіc activity of neutrocytes and the ways of it arepossible correction at of patients from by the acute coronarysyndrom. Fіzіol J. 2011; 57(2): 35-42 [Ukrainian].
© National Academy of Sciences of Ukraine, Bogomoletz Institute of Physiology, 2014-2024.